morphic
therapeutic
announces
first
healthy
volunteers
dosed
phase
clinical
trial
first
orally
available
integrin
inhibitor
mint
platform
enter
clinic
inhibitor
α
β
integrin
development
treat
inflammatory
bowel
disease
phase
program
assess
safety
pharmacokinetics
well
α
β
receptor
occupancy
clinically
relevant
biomarker
waltham
globe
newswire
morphic
therapeutic
nasdaq
morf
biopharmaceutical
company
developing
new
generation
oral
integrin
therapies
treatment
serious
chronic
diseases
today
announced
first
healthy
volunteers
received
phase
clinical
trial
designed
evaluate
safety
pharmacokinetic
profile
addition
predictive
pharmacodynamic
signals
clinical
development
oral
small
molecule
inhibitor
α
β
integrin
treatment
inflammatory
bowel
disease
ibd
initial
focus
ulcerative
colitis
uc
morphic
designed
mint
platform
unique
platform
discovery
development
oral
integrin
drugs
highly
selective
potent
orally
administered
inhibitor
α
β
integrin
target
ibd
initiation
clinical
trials
marks
major
step
forward
effort
stated
peter
linde
md
chief
medical
officer
morphic
therapeutic
based
extensive
preclinical
data
package
believe
selectively
target
clinically
validated
mechanism
approved
injectable
antibody
vedolizumab
utilizing
substantially
convenient
oral
small
molecule
phase
trial
designed
generate
safety
pharmacokinetic
data
well
provide
key
measures
α
β
receptor
occupancy
multiple
doses
evaluated
program
results
may
provide
early
clinical
expect
present
data
major
medical
conference
first
half
next
phase
clinical
trial
phase
clinical
trial
designed
evaluate
safety
pharmacokinetics
pharmacodynamics
dosed
twice
daily
across
three
parts
enrolling
least
healthy
volunteers
initial
part
phase
trial
evaluate
single
ascending
doses
volunteers
across
five
dose
cohorts
second
part
trial
evaluate
multiple
ascending
doses
volunteers
across
least
three
dose
cohorts
third
part
evaluate
effect
food
pharmacokinetic
effects
two
cohorts
six
subjects
receiving
fed
fasting
states
phase
program
designed
generate
important
receptor
occupancy
data
dose
cohort
could
potentially
provide
early
clinical
dose
selection
guidance
use
future
studies
morphic
developing
selective
oral
small
molecule
inhibitor
α
β
integrin
patients
inflammatory
bowel
disease
ibd
α
β
clinically
validated
target
treatment
ibd
success
approved
injectable
antibody
therapeutic
vedolizumab
designed
block
interactions
α
β
surface
lymphocytes
mucosal
endothelial
cell
ligand
substantially
reducing
lymphocyte
migration
bloodstream
intestinal
mucosal
tissues
causing
inflammation
associated
ibd
inflammatory
bowel
disease
inflammatory
bowel
disease
ibd
comprises
several
autoimmune
conditions
characterized
chronic
inflammation
gastrointestinal
tract
ulcerative
colitis
crohn
disease
two
common
types
ibd
ulcerative
colitis
inflammation
limited
lining
colon
whereas
crohn
disease
inflammation
segmentally
affect
part
gastrointestinal
tract
entire
thickness
bowel
wall
symptoms
conditions
include
persistent
diarrhea
abdominal
pain
rectal
bleeding
weight
loss
fatigue
approved
medications
may
adequately
control
symptoms
many
patients
develop
complications
require
surgical
removal
colon
rectum
according
report
crohn
colitis
foundation
november
approximately
people
living
ulcerative
colitis
crohn
disease
united
states
new
cases
diagnosed
per
year
among
fda
approved
therapies
use
moderate
severe
ibd
vedolizumab
injectable
monoclonal
antibody
inhibitor
integrin
α
β
morphic
therapeutic
morphic
therapeutic
biopharmaceutical
company
developing
new
generation
oral
integrin
therapies
treatment
serious
chronic
diseases
including
autoimmune
cardiovascular
metabolic
diseases
fibrosis
cancer
collaboration
abbvie
janssen
schrödinger
morphic
advancing
pipeline
discovery
activities
using
proprietary
mint
technology
platform
leverages
company
unique
understanding
integrin
structure
biology
information
visit
cautionary
note
regarding
statements
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
including
limited
mint
platform
ability
discover
drug
candidates
morphic
plans
develop
commercialize
oral
integrin
therapeutics
execution
phase
clinical
trial
designed
expectations
safety
efficacy
timing
ability
commence
complete
clinical
studies
obtain
regulatory
approvals
candidates
development
ability
treat
inflammatory
bowel
disease
related
indications
statements
including
words
believe
plan
continue
expect
develop
signal
potential
ongoing
statements
future
tense
statements
statements
involve
risks
uncertainties
well
assumptions
fully
materialize
prove
incorrect
could
cause
results
differ
materially
expressed
implied
statements
statements
subject
risks
uncertainties
may
cause
morphic
actual
activities
results
differ
significantly
expressed
statement
including
risks
uncertainties
press
release
risks
set
forth
filings
securities
exchange
commission
including
morphic
partner
ability
develop
obtain
regulatory
approval
commercialize
product
candidate
morphic
ability
protect
intellectual
property
potential
impact
pandemic
sufficiency
cash
cash
equivalents
investments
fund
operations
statements
speak
date
hereof
morphic
specifically
disclaims
obligation
update
statements
reasons
actual
results
might
differ
whether
result
new
information
future
events
otherwise
except
required
law
contacts
morphic
therapeutic
chris
erdman
media
contact
tom
donovan
ten
bridge
communications
tom
